The 10-second takeaway
For the quarter ended March 31 (Q1), Bristol-Myers Squibb met expectations on revenues and earnings per share.
Compared to the prior-year quarter, revenue grew and GAAP earnings per share increased.
Margins expanded across the board.
Bristol-Myers Squibb booked revenue of $5.25 billion. The 16 analysts polled by S&P Capital IQ predicted a top line of $5.27 billion on the same basis. GAAP reported sales were 4.8% higher than the prior-year quarter's $5.01 billion.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $0.64. The 18 earnings estimates compiled by S&P Capital IQ averaged $0.64 per share. GAAP EPS of $0.64 for Q1 were 10% higher than the prior-year quarter's $0.58 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 75.2%, 150 basis points better than the prior-year quarter. Operating margin was 34.7%, 40 basis points better than the prior-year quarter. Net margin was 21.0%, 130 basis points better than the prior-year quarter.
Next quarter's average estimate for revenue is $4.53 billion. On the bottom line, the average EPS estimate is $0.50.
Next year's average estimate for revenue is $18.01 billion. The average EPS estimate is $1.96.
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 1,651 members out of 1,758 rating the stock outperform, and 107 members rating it underperform. Among 440 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 422 give Bristol-Myers Squibb a green thumbs-up, and 18 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Bristol-Myers Squibb is outperform, with an average price target of $33.72.
Can your retirement portfolio provide you with enough income to last? You'll need more than Bristol-Myers Squibb. Learn about crafting a smarter retirement plan in "The Shocking Can't-Miss Truth About Your Retirement." Click here for instant access to this free report.
- Add Bristol-Myers Squibb to My Watchlist.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.